Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Researchers map how measles virus spreads in human brain

    Mayo Clinic researchers mapped how the measles virus mutated and spread in the brain of a person who succumbed to a rare, lethal brain disease. New cases of this disease, which is a complication of the measles virus, may occur as measles reemerges among the unvaccinated, say researchers.

  • AstraZeneca to acquire Gracell

    AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc, a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.

  • Bristol Myers Squibb adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

    Bristol Myers Squibb and RayzeBio, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for USD 62.50 per share in cash, for a total equity value of approximately 4.1 billion USD, or 3.6 billion USD net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

  • Finding that statins could slow dementia stimulates further research

    Blood fat-lowering statins could slow the progression of Alzheimer's disease, at least for some patients. This is the result of a new study led by Karolinska Institutet published in Alzheimer Research and Therapy. But the researchers are cautious in their interpretations and see the results as a first step in a research journey that may eventually provide the answer.

  • Protein-protein interaction discovery unveils Down syndrome's molecular mechanism potential

    Down syndrome, a congenital disorder stemming from abnormal cell division and differentiation, is most common in newborns fated to neurodevelopmental delays and other health complications.

  • A novel angle on type 1 diabetes: RNA editing disruption mimics early-stage disease with no involvement of virus

    A recent study by researchers at the Hebrew University-Hadassah Medical School, Bar-Ilan University and Vanderbilt University has developed a new paradigm for early stages of type 1 diabetes (T1D), suggesting a new etiology that does not involve viral infection.

  • Enzymes Can’t Tell Artificial DNA From the Real Thing

    The genetic alphabet contains just four letters, referring to the four nucleotides, the biochemical building blocks that comprise all DNA. Scientists have long wondered whether it’s possible to add more letters to this alphabet by creating brand-new nucleotides in the lab, but the utility of this innovation depends on whether or not cells can actually recognize and use artificial nucleotides to make proteins.

  • CDSCO recommends not to use anti-cold syrup in children

    CDSCO recommends widely used anti-cold syrup not to be used in children below 4 years of age, after recommendation from SEC.

    The FDC of Chlorpheniramine Maleate and Phenylephrine HCl was declared as rational by Prof. Kokate committee and based on the recommendation of the committee, this office has issued NOC for continued manufacturing and marketing of subject FDC on 17.07.2015 under the 18 months policy decision.

  • WHO adds the R21/Matrix-M malaria vaccine as prequalified

    WHO has added the R21/Matrix-M malaria vaccine to its list of prequalified vaccines. In October 2023, WHO recommended its use for the prevention of malaria in children following the advice of the WHO Strategic Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory Group. The prequalification means larger access to vaccines as a key tool to prevent malaria in children with it being a prerequisite for vaccine procurement by UNICEF and funding support for deployment by Gavi, the Vaccine Alliance.

  • Takeda announces China NMPA approval of LIVTENCITY

    Takeda announced that LIVTENCITY (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. LIVTENCITY is the first and only inhibitor of CMV-specific UL97 protein kinase in China for this indication.

Subscribe to Pharma News